FM
ARQT icon

Frazier Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Frazier Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,434,232
Closed -$175M – 5
2021
Q4 		$175M Hold
8,434,232
– – 13.47% 1
2021
Q3 		$201M Hold
8,434,232
– – 16.12% 1
2021
Q2 		$230M Sell
8,434,232
-2,108,558
-20% -$59.4M 21.23% 1
2021
Q1 		$305M Hold
10,542,790
– – 24.46% 1
2020
Q4 		$297M Hold
10,542,790
– – 22.84% 1
2020
Q3 		$309M Hold
10,542,790
– – 27.73% 1
2020
Q2 		$319M Hold
10,542,790
– – 28% 1
2020
Q1 		$314M Buy
+10,542,790
New +$283M 35.62% 1

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Frazier Management's ARQT Position: Q1 2022 in Review

Frazier Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2022, closing a stake of 8,434,232 shares — an estimated $175M sold.

Frazier Management first reported a position in ARQT in Q1 2020 and held it in 8 quarters. The position peaked at $319M in Q2 2020. 106 funds tracked by Wall St. Rank hold ARQT as of Q1 2022.

  • Frazier Management reported no remaining Arcutis Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 8,434,232 Arcutis Biotherapeutics shares in Q1 2022, an estimated $175M.
  • Frazier Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 8 quarters.
  • Frazier Management's Arcutis Biotherapeutics position peaked at $319M in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.